Customized Solutions for Systemic Sclerosis (SSc) Animal Model Development

Download

Systemic sclerosis (SSc) is a chronic, multisystem autoimmune disorder characterized by progressive fibrosis of the skin and internal organs, vasculopathy, and immune dysregulation. Despite advances in understanding its pathogenesis, limited therapy options exist. Reliable and relevant animal models remain essential for deciphering disease mechanisms and evaluating novel therapeutic candidates.

Protheragen provides comprehensive preclinical research services spanning diagnostic development, therapeutic development, disease model development, and preclinical research. Customized systemic sclerosis animal model development is offered alongside end‑to‑end study capabilities, enabling rigorous evaluation of anti‑fibrotic, immunomodulatory, and vascular‑targeting interventions from early target validation through regulatory‑ready data packages.

Overview of Systemic Sclerosis (SSc) Animal Models

No single animal model fully recapitulates the entire spectrum of human SSc; however, well‑established models reproduce key features such as dermal and pulmonary fibrosis, vascular remodeling, and autoantibody production. Commonly utilized models include the bleomycin‑induced dermal and lung fibrosis model, which relies on repeated subcutaneous or intratracheal challenge to mimic inflammation-driven fibrogenesis; and the chronic graft‑versus‑host disease (cGVHD) model, which reproduces sclerodermatous changes following allogeneic bone marrow transplantation. Additional models, such as the HOCl‑induced models, offer alternative routes to study immune‑mediated fibrosis. Each model presents distinct advantages and limitations regarding time course, organ involvement, and translational relevance, requiring careful selection based on the specific research question.

Applications of Systemic Sclerosis (SSc) Animal Models

Systemic sclerosis animal models serve as indispensable tools across multiple stages of preclinical drug development and mechanistic investigation. Key applications include the evaluation of anti‑fibrotic compounds targeting TGF‑β, CTGF, or lysyl oxidase‑like 2 (LOXL2) pathways; and assessment of immunomodulatory biologics or small molecules aimed at B cells, T cells, or type I interferon signaling.

Workflow for Systemic Sclerosis (SSc) Animal Model Development

A systematic, stepwise workflow ensures reproducibility, regulatory alignment, and meaningful translational data for each systemic sclerosis model study. From model selection to final data delivery, each phase is documented under standard operating procedures.

• Model Selection and Optimization: Choose among bleomycin‑induced, HOCl‑induced, or cGVHD models based on target fibrosis profile (skin, lung, or systemic) and disease timeline (acute vs. chronic).
• Model Induction: Perform model induction following validated protocols; randomize animals into therapy groups (vehicle, positive control, test articles) stratified by body weight or baseline disease markers.
• Dosing and Monitoring: Administer test compounds via systemic (oral, IP, SC) or local (intradermal, intratracheal) routes; monitor skin thickness, grip strength, body weight, and clinical signs longitudinally.
• Endpoint Collection and Tissue Processing: Harvest skin, lung, heart, kidney, and esophagus at predefined time points; process for histopathology, hydroxyproline assay, immunohistochemistry, and molecular analysis.
• Data Analysis and Reporting: Data are analyzed using appropriate statistical methods and presented in study reports compliant with standards.

Integrated Preclinical Research Services for Systemic Sclerosis (SSc)

Beyond systemic sclerosis model development, Protheragen delivers fully integrated preclinical services that span the entire drug development continuum, from early discovery support through IND‑enabling studies. Each service area is designed to interface seamlessly with the systemic sclerosis model platform, enabling coordinated execution of efficacy, safety, and biomarker studies under an integrated project management structure.

Case Study 01-Hypochlorous Acid (HOCL) Induced Model

A hypochlorous acid (HOCl)‑induced systemic sclerosis mouse model was developed to recapitulate key features of systemic sclerosis, including dermal and pulmonary fibrosis, inflammatory infiltration, and autoantibody production. Intradermal injections of HOCl were administered daily on the dorsal skin of female BALB/c mice (6-8 weeks old) over a continuous 42‑day induction period. Endpoint assessments were performed, including body weight, dermal fibrosis via back skin thickness and histomorphometry, inflammatory cytokine profiles, collagen accumulation in lung tissue, and serum autoantibody levels against DNA topoisomerase I.

Marked increases in dorsal skin thickness and dermal fibrotic changes were observed in the induced group compared to vehicle controls, accompanied by histopathological alterations including inflammatory cell infiltration, hyperkeratosis, dermal degeneration, and necrosis. Significantly elevated levels of pro‑inflammatory and pro‑fibrotic cytokines were detected in the skin at the injection site. Collagen content in lung tissue, quantified by Sircol assay, showed substantial accumulation in the induced group relative to controls. Furthermore, serum autoantibody responses against DNA topoisomerase I were markedly elevated in HOCl‑treated mice, demonstrating a humoral autoimmune response characteristic of systemic sclerosis.

The HOCl‑induced model successfully recapitulated the systemic sclerosis features, dermal and pulmonary fibrosis, local and systemic inflammation, and autoantibody production, making it a valuable platform for evaluating anti‑fibrotic and immunomodulatory therapies.

Case Study 02-Sclerodermatous Chronic GVHD (Scl-cGVHD) Model

A sclerodermatous chronic graft‑versus‑host disease (Scl‑cGVHD) mouse model was developed by allogeneic bone marrow transplantation. Recipient female BALB/c mice were irradiated with 8 Gy and subsequently injected intravenously with T cell‑depleted bone marrow cells combined with unmanipulated splenocytes from donor male B10.D2 mice. A neutralizing monoclonal antibody or a control antibody was administered via intraperitoneal injection starting on day 7 post‑transplantation and continued twice weekly until day 35. Tissue collection and endpoint assessments were performed on day 42 post‑BMT.

On day 42 post-transplantation, allogeneic control mice exhibited progressive skin fibrosis, alopecia, and reduced body weight compared to syngeneic controls, whereas antibody-treated mice showed significantly improved skin scores and better body weight maintenance. Dermal thickening, increased collagen deposition (Masson's trichrome area and soluble collagen content), and elevated numbers of α SMA-positive myofibroblasts and CD3-positive T cells in skin sections were observed in the allogeneic control group; all these parameters were markedly reduced in the antibody-treated group. Lung tissue analysis further revealed that allogeneic control mice developed pulmonary fibrosis and inflammation, as evidenced by increased trichrome‑stained area, elevated soluble collagen content, and higher α‑SMA immunostaining, all of which were attenuated by antibody therapy.

The Scl‑cGVHD model faithfully recapitulated the cutaneous and pulmonary fibrosis, inflammatory cell infiltration, and weight loss characteristic of chronic sclerodermatous GVHD, providing a robust platform for evaluating immunomodulatory and anti‑fibrotic interventions in a transplantation‑based systemic sclerosis model.

Why Choose Us?

• Specialized Expertise: Deep understanding of systemic sclerosis pathogenesis and hands‑on experience across multiple model systems, with a proven track record in anti‑fibrotic and immunomodulatory drug testing.
• Customized Solutions: Flexible study designs allow for the integration of specific disease triggers and endpoints tailored to unique therapeutic goals.
• Rigorous Validation: Strict quality control protocols and standardized operating procedures guarantee the reproducibility and scientific integrity of all preclinical data.
• Accelerated Timelines: Streamlined project management and state-of-the-art facilities enable rapid data generation to support critical decision-making in drug development.

Contact Us

A well‑characterized and relevant animal model is the cornerstone of successful translational research in systemic sclerosis. Protheragen’s established systemic sclerosis model platform, coupled with comprehensive diagnostic, therapeutic, disease model, and preclinical research capabilities, provides a reliable partner for advancing anti‑fibrotic and immunomodulatory therapies from target validation to regulatory submission. For detailed model characterization data, custom study proposals, or to discuss specific research needs, please contact our scientific team.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Rare Disease Diagnostics Development
• Rare Disease Therapeutics Development
• Drug Repurposing Service
• Rare Disease Model Development Services
• Drug Safety Evaluation Services
• Pharmacokinetics Services